Elevated Triglycerides (TG) Study
Study Background
Certain cardiovascular diseases can develop when fatty deposits, or plaque, build up in the arteries, leading to blockages that restrict blood flow. These blockages can cause heart attacks, strokes, and other cardiovascular problems.
Despite advancements in treatment, people living with these cardiovascular diseases continue to face a higher risk of heart disease and related complications, primarily due to factors like elevated triglyceride (TG) levels.
This clinical trial is investigating the effects of a new investigational medication, on reducing cardiovascular risks in adults with these types of cardiovascular diseases. The investigational medication aims to lower TG and reduce insulin resistance. As a participant, you will be randomly assigned to receive either the study medication or a placebo.
Study Details
The study would require you to come in for 11 visits over a 10-month period. Visits will range from 30 minutes to 3 hours. You will be required to self-administer the study injection or placebo once every two weeks. At the visits we will check your medical history, conduct physical examinations including ECG’s and draw blood.
Eligibility Criteria
- Aged 18 to 75 years
- Non-fasting triglyceride (TG) value ≥175 mg/dL (1.98 mmol/L) – Tested at screening visit
- Fasting TG value ≥ 150 mg/dL (≥ 1.69 mmol/L) – Tested at 2nd visit









